Loading
A phase 3 trial of Ribociclib in HR-positive / HER2-negative breast cancer, run by Olema Pharmaceuticals, Inc., now recruiting.
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer is a phase 3 interventional study registered as NCT07085767 by Olema Pharmaceuticals, Inc., with 1000 participants planned, started 2025-11-03 and due to reach its primary completion in 2028-12. Interventions recorded: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole and Palazestrant matching-placebo.
Shares Advanced Accelerator Applications (Novartis), Ribociclib, CDK4/6 inhibitors, Novartis and the tag pipeline.
Shares Olema Pharmaceuticals, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Ribociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, HR-positive / HER2-negative breast cancer and the tag pipeline.